Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cristina P Rodriguez

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Head & Neck|July 14, 2023
Radiation therapy for low- and high-risk perineural invasion in head and neck cutaneous squamous cell carcinoma: Clinical outcomes and patterns of failureTheodore A Gobillot, Matthew Greer, Upendra Parvathaneni, et al.
JCI Insight|July 27, 2018
The mutational landscape of recurrent versus nonrecurrent human papillomavirus-related oropharyngeal cancerR Alex Harbison, Mark Kubik, Eric Q Konnick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2018
A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell CarcinomaEduardo Méndez, Cristina P Rodriguez, Michael C Kao, et al.
Oral Oncology|December 20, 2023
PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion studyRenata Ferrarotto, Paul L Swiecicki, Dan P Zandberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2019
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland CancerCristina P Rodriguez, Qian Vicky Wu, Jenna Voutsinas, et al.
Head & Neck|April 11, 2016
Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experienceDaisuke Araki, Mary W Redman, Renato Martins, et al.
Cancer Medicine|February 22, 2023
Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitorsCassie Pan, Qian Vicky Wu, Jenna Voutsinas, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 23, 2020
FOXM1 drives HPV+ HNSCC sensitivity to WEE1 inhibitionAhmed Diab, Hakan Gem, Jherek Swanger, et al.
BMC Cancer|November 15, 2024
Development of a prognostic signature for overall survival using peripheral blood biomarkers in head and neck squamous cell carcinoma treated with immune checkpoint inhibitorsCassie Pan, Kevin Ng, Jenna Voutsinas, et al.
Journal of Gastrointestinal Cancer|October 14, 2016
Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative OutcomesMichael J McNamara, David J Adelstein, Daniela S Allende, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Head & Neck|July 14, 2023
Radiation therapy for low- and high-risk perineural invasion in head and neck cutaneous squamous cell carcinoma: Clinical outcomes and patterns of failureTheodore A Gobillot, Matthew Greer, Upendra Parvathaneni, et al.
JCI Insight|July 27, 2018
The mutational landscape of recurrent versus nonrecurrent human papillomavirus-related oropharyngeal cancerR Alex Harbison, Mark Kubik, Eric Q Konnick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2018
A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell CarcinomaEduardo Méndez, Cristina P Rodriguez, Michael C Kao, et al.
Oral Oncology|December 20, 2023
PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion studyRenata Ferrarotto, Paul L Swiecicki, Dan P Zandberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2019
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland CancerCristina P Rodriguez, Qian Vicky Wu, Jenna Voutsinas, et al.
Head & Neck|April 11, 2016
Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experienceDaisuke Araki, Mary W Redman, Renato Martins, et al.
Cancer Medicine|February 22, 2023
Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitorsCassie Pan, Qian Vicky Wu, Jenna Voutsinas, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 23, 2020
FOXM1 drives HPV+ HNSCC sensitivity to WEE1 inhibitionAhmed Diab, Hakan Gem, Jherek Swanger, et al.
BMC Cancer|November 15, 2024
Development of a prognostic signature for overall survival using peripheral blood biomarkers in head and neck squamous cell carcinoma treated with immune checkpoint inhibitorsCassie Pan, Kevin Ng, Jenna Voutsinas, et al.
Journal of Gastrointestinal Cancer|October 14, 2016
Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative OutcomesMichael J McNamara, David J Adelstein, Daniela S Allende, et al.
Pageof 7